DiaMedica Therapeutics Inc (DMAC) - Total Assets
Based on the latest financial reports, DiaMedica Therapeutics Inc (DMAC) holds total assets worth $53.08 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DiaMedica Therapeutics Inc - Total Assets Trend (2004–2025)
This chart illustrates how DiaMedica Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see DiaMedica Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
DiaMedica Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
DiaMedica Therapeutics Inc's total assets of $53.08 Million consist of 98.8% current assets and 1.2% non-current assets. Review DiaMedica Therapeutics Inc balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.5% |
| Accounts Receivable | $258.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how DiaMedica Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See DiaMedica Therapeutics Inc (DMAC) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DiaMedica Therapeutics Inc's current assets represent 98.8% of total assets in 2025, an increase from 12.8% in 2004.
- Cash Position: Cash and equivalents constituted 25.5% of total assets in 2025, up from 3.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 78.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
DiaMedica Therapeutics Inc Competitors by Total Assets
Key competitors of DiaMedica Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
DiaMedica Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.11 | 8.02 | 15.02 |
| Quick Ratio | 9.11 | 8.02 | 15.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $46.62 Million | $32.76 Million | $20.19 Million |
DiaMedica Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between DiaMedica Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.81 |
| Latest Market Cap to Assets Ratio | 5.55 |
| Asset Growth Rate (YoY) | 32.4% |
| Total Assets | $61.37 Million |
| Market Capitalization | $340.54 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values DiaMedica Therapeutics Inc's assets at a significant premium (5.55x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: DiaMedica Therapeutics Inc's assets grew by 32.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for DiaMedica Therapeutics Inc (2004–2025)
The table below shows the annual total assets of DiaMedica Therapeutics Inc from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $61.37 Million | +32.42% |
| 2024-12-31 | $46.34 Million | -14.43% |
| 2023-12-31 | $54.16 Million | +57.46% |
| 2022-12-31 | $34.40 Million | -24.49% |
| 2021-12-31 | $45.55 Million | +62.13% |
| 2020-12-31 | $28.09 Million | +210.34% |
| 2019-12-31 | $9.05 Million | -50.64% |
| 2018-12-31 | $18.34 Million | +917.70% |
| 2017-12-31 | $1.80 Million | -3.79% |
| 2016-12-31 | $1.87 Million | +742.13% |
| 2015-12-31 | $222.41K | -21.02% |
| 2014-12-31 | $281.59K | -90.31% |
| 2013-12-31 | $2.91 Million | -24.46% |
| 2012-12-31 | $3.85 Million | -39.19% |
| 2011-12-31 | $6.33 Million | -30.30% |
| 2010-12-31 | $9.08 Million | +628.83% |
| 2009-12-31 | $1.25 Million | -58.45% |
| 2008-12-31 | $3.00 Million | -30.89% |
| 2007-12-31 | $4.34 Million | +513.58% |
| 2006-12-31 | $706.86K | +25.64% |
| 2005-12-31 | $562.60K | +160.07% |
| 2004-12-31 | $216.33K | -- |
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more